trey parker semaglutide blood in stool while on Can GLP-1 Medications Cause Blood in Stool? Causes, Risks & When to Se South Park' to Tackle Ozempic

Wegovy is indicated for lowering body weight in obese and overweight patients with at least one weight-related disease and treating metabolic dysfunction-associated steatohepatitis (MASH) in patients with mild to moderate liver fibrosis

With significant or rapid weight loss, particularly when driven by GLP-1 drugs, several mechanisms converge: Loss of underlying fat volume removes structural support Collagen and elastin fibres become stretched and fragmented Speed of weight loss outpaces skin contraction While some rebound occurs naturally, significant laxity can be permanent, especially after large weight reductions

This direct central nervous system activity helps explain the mood improvements many users experience

Clinically, many patients report fewer depressive symptoms while taking GLP-1 agonists, sometimes alongside reduced antidepressant use

Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range